The VEGFA Polyclonal Antibody (CAB0280) is an essential tool for research involving VEGFA, a key player in angiogenesis and vascular permeability in various biological processes. This antibody, produced in rabbits, has high reactivity with human samples and has been validated for use in Western blot applications. By binding to the VEGFA protein, it allows for accurate detection and analysis in different cell types, making it suitable for studies in cancer biology, cardiovascular diseases, and other fields related to vascular biology.
VEGFA, also known as vascular endothelial growth factor A, is a crucial factor in promoting the formation of new blood vessels and enhancing vascular permeability in physiological and pathological conditions. Its involvement in angiogenesis has made it a significant target for research into cancer progression, ischemic diseases, and ocular disorders. Understanding the regulation and function of VEGFA is essential for developing strategies to manipulate angiogenesis for therapeutic purposes in various diseases.
Product Name:
VEGF Rabbit Polyclonal Antibody
SKU:
CAB0280
Size:
20uL, 100uL
Isotype:
IgG
Host Species:
Rabbit
Reactivity:
Human,Mouse,Rat
Immunogen:
A synthetic peptide corresponding to a sequence within amino acids 100-200 of human VEGFA (NP_001165094.1).
This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site. The levels of VEGF are increased during infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), thus promoting inflammation by facilitating recruitment of inflammatory cells, and by increasing the level of angiopoietin II (Ang II), one of two products of the SARS-CoV-2 binding target, angiotensin-converting enzyme 2 (ACE2). In turn, Ang II facilitates the elevation of VEGF, thus forming a vicious cycle in the release of inflammatory cytokines.
Purification Method:
Affinity purification
Gene ID:
7422
Storage Buffer:
Store at -20℃. Avoid freeze / thaw cycles.Buffer: PBS with 0.09% Sodium azide,50% glycerol,pH7.3.
Western blot analysis of various lysates, using VEGFA Rabbit pAb (CAB0280) at 1:1000 dilution.Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (CABS014) at 1:10000 dilution.Lysates/proteins: 25ug per lane.Blocking buffer: 3% nonfat dry milk in TBST.Detection: ECL Enhanced Kit (AbGn00021).Exposure time: 30s.
